Patent Claims

1. Obinutuzumab, for use in the treatment of cancer in combination with a CD79b antibody-drug conjugate anti-CD79b-MC-vc-PAB-MMAE, wherein the anti-CD79b antibody in said CD79b antibody-drug conjugate is huMA79b.v28 comprising the light chain variable domain SEQ ID NO: 69 and the heavy chain variable domain SEQ ID NO: 70.

2. Obinutuzumab for use according to claim 1, characterized in that said cancer is a CD20 expressing cancer.

3. Obinutuzumab for use according to any one of claims 1 to 2, characterized in that said CD20 expressing cancer is a lymphoma or lymphocytic leukemia.

4. Obinutuzumab for use according to any one of claims 1 to 3, characterized in that one or more additional other cytotoxic, chemotherapeutic or anti-cancer agents, or compounds or ionizing radiation that enhance the effects of such agents are to be administered.

6. The composition for use according to claim 5, characterized in that one or more additional other cytotoxic, chemotherapeutic or anti-cancer agents, or compounds or ionizing radiation that enhance the effects of such agents are to be administered.

7. Use of obinutuzumab in the manufacture of a medicament for the treatment of a CD20 expressing cancer in combination with a CD79b antibody-drug conjugate anti-CD79b-MC-vc-PAB-MMAE, wherein the anti-CD79b antibody in said CD79b antibody-drug conjugate is huMA79b.v28 comprising the light chain variable domain SEQ ID NO: 69 and the heavy chain variable domain SEQ ID NO: 70.

8. The use according to claim 7, characterized in that said CD20 expressing cancer is a lymphoma or lymphocytic leukemia.

9. The use according to claim 7 or 8, characterized in that one or more additional other cytotoxic, chemotherapeutic or anti-cancer agents, or compounds or ionizing radiation that enhance the effects of such agents are to be administered.